Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells

Cytokines, Cellular and Molecular Therapy

Volumn 5, Issue 3, 1999, Pages 139-144

  Nasi, M Laura ^a   Lieberman, Phillip ^a   Busam, Klaus J ^a   Prieto, Victor ^a   Panageas, Katherine S ^a   Lewis, Jonathan J ^a   Houghton, Alan N ^a   Chapman, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Dendritic cell; Growth factor; T cell; Vaccine

Indexed keywords

BLOOD CLOTTING FACTOR 13A; CD45 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; PROTEIN S 100;

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN TISSUE; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; INTRADERMAL DRUG ADMINISTRATION; MACROPHAGE; MALE; MELANOMA; PRIORITY JOURNAL; SKIN METASTASIS; T LYMPHOCYTE; TUMOR BIOPSY;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRADERMAL; MELANOMA; SKIN NEOPLASMS;

EID: 0032886907     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. van der Bruggen P, Traversari C, Chomez P et al, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254: 1643-47.
2. Wolfel T, Van Pel A, Brichard V et al, Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol (1994) 24: 759-64.
3. Bakker ABH, Schreurs MWJ, de Boer AJ et al, Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med (1994) 179: 1005-9.
4. Kawakami Y, Eliyahu S, Sakaguchi K et al, Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med (1994) 180: 347-52.
5. Wang R-F, Robbins PF, Kawakami Y et al, Identification of a gene encoding a melanoma tumor recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med (1995) 181: 799-804.
6. Lupetti R, Pisarra P, Verrecchia A et al, Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J Exp Med (1998) 188: 1005-16.
7. Alexander MA, Bennicelli J, Guerry D IV, Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early, disease. J Immunol (1989) 142: 4070-8.
8. Huang AY, Golumbek P, Ahmadzadeh M et al, Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 264: 961-5.
9. Witmer-Pack MD, Oliver W, Valinsky J et al, Granulocyte/ macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med (1987) 166: 1484-98.
10. Kaplan G, Walsh G, Guido LS et al, Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med (1992) 175: 1717-28.
11. Hamilton WB, Helling F, Lloyd KO, Livingston PO, Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer (1993) 53: 566-73.
12. Thomson TM, Mattes MJ, Roux L et al, Pigmentation-associated glycoprotein of human melanomas and melanocytes: definition with a mouse monoclonal antibody. J Invest Dermatol (1985) 85: 169-74.
13. Creekmore SP, Longo DL, Urba WJ, Principles of the clinical evaluation of biologic agents. In: Biologic Therapy of Cancer (ed VT DeVita Jr, S Hellman, SA Rosenberg) 67-86. JB Lippincott, Philadelphia, 1991.
14. Hart DNJ, Dendritic cells: unique leukocyte populations which control the primary immune response. Blood (1997) 90: 3245-87.
15. Young J, Dendritic cells: expansion and differentiation with hematopoietic growth factors. Curr Opin Hematol (1999) 6: 135-44.
16. Hahne M, Rimoldi D, Schröter M et al, Melanoma cell expression of fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 274: 1363-6.
17. Chomarat P, Bell D, Palucka KA et al, Selective distribution of dendritic cells in breast carcinoma. Proc Am Soc Oncol (1999) 40: 85.
18. Dyall R, Bowne WB, Weber LW et al, Heteroclitic immunization induces tumor immunity. J Exp Med (1998) 188: 1553-61.
19. Si Z, Hersey P, Coates AS, Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res (1996) 6: 247-55.